Notice of US patent allowance
Notice of US patent allowance for Medherant’s testosterone patch for post-menopausal women 6 September 2024 (Coventry, UK). Medherant is pleased to announce that it has received the notice of allowance from the US Patent and Trademark Office for...
Preliminary results of clinical study of Medherant’s testosterone patch for post-menopausal women
10 April 2024 (Coventry, UK). Medherant is pleased to announce the preliminary results of the Phase I study of its testosterone patch technology being conducted at Hammersmith Medicines Research (HMR; London). Preliminary results from this study demo...
Medherant transdermal patch development collaboration with Bayer
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine...